Xvivo Perfusion AB (publ)
XVIPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14,321,954 | $9,646,830 | $6,314,229 | $8,074,294 |
| - Cash | $415,521 | $545,788 | $246,545 | $398,696 |
| + Debt | $34,043 | $31,437 | $10,005 | $5,721 |
| Enterprise Value | $13,940,476 | $9,132,479 | $6,077,689 | $7,681,319 |
| Revenue | $822,415 | $597,542 | $415,292 | $258,386 |
| % Growth | 37.6% | 43.9% | 60.7% | – |
| Gross Profit | $616,415 | $445,111 | $296,956 | $188,279 |
| % Margin | 75% | 74.5% | 71.5% | 72.9% |
| EBITDA | $288,924 | $80,537 | $38,722 | $39,198 |
| % Margin | 35.1% | 13.5% | 9.3% | 15.2% |
| Net Income | $172,182 | $91,820 | $18,427 | $8,152 |
| % Margin | 20.9% | 15.4% | 4.4% | 3.2% |
| EPS Diluted | 5.44 | 3.07 | 0.62 | 0.28 |
| % Growth | 77.2% | 395.2% | 121.4% | – |
| Operating Cash Flow | $111,290 | $46,287 | $27,856 | -$12,059 |
| Capital Expenditures | -$70,731 | -$143,936 | -$130,946 | -$94,074 |
| Free Cash Flow | $40,559 | -$97,649 | -$103,090 | -$106,133 |